目的：观察疏血通注射液治疗急性脑梗死的疗效和安全性。方法：110 例急性脑梗死患者随机均分为对照组和观察组。

对照组患者给予甘露醇、拜阿司匹林、阿托伐他汀、降糖药物等常规治疗；观察组患者在对照组治疗的基础上给予疏血通注射液6

ml加入0.9％氯化钠注射液250 ml中，静脉滴注，每日3 次。两组患者疗程均为15 d。观察两组患者的临床疗效，治疗前后美国国

立卫生研究院卒中量表（NIHSS）评分和特异性烯醇化酶（NSE）、超敏C反应蛋白（hs-CRP）、肿瘤坏死因子（TNF）-α水平及不良反

应发生情况。结果：治疗后，两组患者NIHSS评分和NSE、hs-CRP、TNF-α水平均显著低于同组治疗前，且观察组低于对照组，差

异均有统计学意义（P＜0.05）；观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。两组患者治疗期间均未见明

显不良反应发生。结论：在常规治疗的基础上给予疏血通注射液治疗急性脑梗死的疗效和安全性均较好。

OBJECTIVE：To observe the efficacy and safety of Shuxuetong injection in the treatment of acute cerebral infarction（

ACI）. METHODS：110 patients with ACI were randomly divided into control group and observation group. Control group

was given mannitol，aspirin，atorvastatin，antidiabetic drugs and other conventional treatment；observation group was additionally

given Shuxuetong injection 6 ml adding into 0.9％ Sodium chloride solution 250 ml by intravenous infusion，3 times a day. The efficacy

in 2 groups was evaluated after 15 d，and the National Institute of Health Stroke Scale（NIHSS）score，neuron specific enolase（

NSE），high-sensitivity C-reactive protein（hs-CRP）and tumor necrosis factor-α（TNF-α）levels before and after treatment and

the incidence of adverse reactions in 2 groups were recorded. RESULTS：After treatment，NIHSS score，NSE，hs-CRP and TNF-α

in 2 groups were significantly lower than before，and observation group was lower than control group，the differences were statistically

significant（P＜0.05）；total effective rate in observation group was significantly higher than control group，the difference was

statistically significant（P＜0.05）. There was no obvious adverse reactions in 2 groups during treatment. CONCLUSIONS：Based on

the conventional treatment，Shuxuetong injection has good efficacy and safety in the treatment of ACI.